Your Wearable Is Worried. What a Declining HRV Actually Means.

He was forty-one. He had been using a Whoop for two years. He logged his sleep, adjusted his training load, took the magnesium, bought the cold plunge. He went to bed at ten. He ate within a feeding window. He did everything that the device and the podcast told him to do.

His HRV was twenty-two milliseconds and dropping.

He came to my office not because he felt sick. He came because the device had been telling him for six months that something was wrong, and he had run out of protocols to try. His words, almost verbatim, match what men in r/whoop write when they hit this wall: the protocol is flawless, the number keeps falling, and no one in the optimization ecosystem can tell them why.

I ordered an ApoB. A fasting insulin. A 24-hour ambulatory blood pressure. And I ordered a coronary calcium CT, which takes eleven minutes and costs about a hundred dollars at most imaging centers.

His CAC score was 142.

He was forty-one years old and had a calcium score of 142. No symptoms. Normal resting heart rate. Normal LDL. A Whoop waving a flag for six months while everyone around him explained the low HRV as a training recovery problem.

It was not a training recovery problem.

The HRV was low because his coronary arteries were accumulating calcium. The autonomic nervous system, which regulates HRV, had been sensing subclinical vascular disease and signaling distress in the only language a wearable can read.

He did not need more magnesium. He needed a statin, a cardiology follow-up, and a serious conversation about what the next twenty years look like if we catch this now versus if we don’t.

We caught it. That is the story I want you to have.

The Mechanism

To understand what a declining HRV number means, you need to understand what the autonomic nervous system is actually doing when it produces that number. This is not abstract physiology. It determines what kind of problem you are dealing with.

The autonomic nervous system has two branches that continuously negotiate control of your heart. The sympathetic branch accelerates the heartbeat, stiffens the beat-to-beat interval, and prepares you for action. The parasympathetic branch, delivered through the vagus nerve, slows the heart, introduces variability between beats, and governs the recovery state. Heart rate variability is the readout of that negotiation. When the vagus nerve is exerting strong influence, each breath cycle modulates cardiac rate noticeably: heart rate accelerates on inhalation and decelerates on exhalation. This respiratory sinus arrhythmia is the primary source of the beat-to-beat variation that wearables measure.

The metric consumer wearables report, RMSSD, captures this precisely. RMSSD stands for root mean square of successive differences, calculated by taking the difference between each pair of consecutive R-R intervals across a measurement window, squaring those differences, averaging them, and taking the square root. The result is a millisecond number that reflects moment-to-moment variation driven almost entirely by vagal activity. Higher RMSSD means stronger parasympathetic tone. Lower RMSSD means the sympathetic branch is running without sufficient vagal counterbalance.

The clinical standard is different. A 24-hour Holter monitor records the electrical signal of the heart continuously and calculates SDNN, the standard deviation of all normal R-R intervals over the full recording. SDNN captures variability across multiple frequencies, including the slower oscillations driven by blood pressure regulation, thermoregulation, and circadian rhythms, not just the respiratory frequency that RMSSD emphasizes. SDNN below 70 milliseconds in the clinical literature is where cardiac risk stratification begins. Wearable RMSSD and clinical SDNN are correlated but not interchangeable. A man comparing his Whoop number to a cutoff from a Holter study is comparing different instruments.

Where the picture becomes clinically important is the signal chain between the vessel wall and the vagus nerve. Healthy endothelium produces nitric oxide continuously, maintaining vascular tone and allowing the autonomic nervous system to modulate cardiac output with low resistance. When the endothelium is dysfunctional, when inflammatory cytokines reduce nitric oxide synthase activity and oxidative stress destroys the nitric oxide that is produced, the system works against elevated resistance. The vagus nerve is sending its signals into a circuit that is stiffer, less responsive, and loaded with inflammatory noise. The signal arrives. The response is blunted. The HRV falls.

There is a second mechanism. Inflammatory cytokines, particularly interleukin-6 and tumor necrosis factor-alpha, act directly on the brainstem nuclei that regulate vagal outflow. Elevated systemic inflammation, the kind that accompanies early atherosclerosis, suppresses the nucleus ambiguus and the dorsal motor nucleus of the vagus, reducing the parasympathetic drive to the heart at the source. A man with hs-CRP of 3.4 mg/L and subclinical coronary disease is experiencing vagal suppression at the neuroanatomical level, not just at the vessel wall. His HRV is low because his brainstem is responding correctly to the biological environment it is in. 4 / Promising

This is the mechanism the wearable industry does not explain and the optimization protocol cannot address.

What the Evidence Shows

The clinical evidence for HRV as a cardiovascular signal spans four decades and crosses from post-infarction populations into apparently healthy men. The hierarchy of evidence matters here.

Kleiger et al., 1987. The foundational study. Published in the American Journal of Cardiology, Kleiger and colleagues followed 808 survivors of acute myocardial infarction and found that SDNN below 50 milliseconds was associated with a 5.3-fold increase in mortality compared to those with SDNN above 100 milliseconds. This was the first demonstration that a time-domain HRV measure derived from a 24-hour recording predicted death in a cardiac population. It established the mechanism: reduced vagal tone removes the anti-arrhythmic protection the parasympathetic system provides to a damaged heart. 5 / Solid

La Rovere et al., 1998, the ATRAMI study. The Autonomic Tone and Reflexes After Myocardial Infarction study enrolled 1,284 patients across European centers and followed them for 21 months after myocardial infarction. Published in the Lancet, the ATRAMI investigators found that SDNN below 70 milliseconds predicted cardiac mortality with a relative risk of 3.2 after adjustment for left ventricular ejection fraction and other clinical variables. Critically, baroreflex sensitivity, a related measure of vagal responsiveness to blood pressure changes, was an independent predictor with a relative risk of 2.8. The two measures combined produced a relative risk above 6.0. This established the prognostic weight of autonomic function in a post-MI population at a level that entered clinical cardiology guidelines. 5 / Solid

Tsuji et al., 1996, Framingham Heart Study. Moving from post-infarction populations to the general community, Tsuji and colleagues analyzed HRV data from 2,501 participants in the Framingham Heart Study. Published in Circulation, they found that reduced SDNN was an independent predictor of cardiovascular events in a generally healthy population, after adjustment for age, sex, smoking, blood pressure, diabetes, and total cholesterol. The relative risk per standard deviation decrease in SDNN was approximately 1.5 to 1.7. This was the first major evidence that HRV carried prognostic information in people without known cardiac disease. 4 / Promising

The CARDIA study. The Coronary Artery Risk Development in Young Adults study tracked cardiovascular risk factor evolution in a cohort enrolled in their 20s and followed across decades. Analyses of HRV within the CARDIA cohort found that lower HRV in young and middle-aged adults was associated with higher rates of subsequent hypertension, metabolic syndrome, and incident cardiovascular events. The CARDIA data are particularly relevant for men in their 30s and 40s who are not yet symptomatic: the HRV signal carries information about cardiovascular risk accumulation before clinical events occur. 4 / Promising

The Copenhagen City Heart Study. This Danish prospective cohort followed over 14,000 participants across multiple decades. Analyses examining HRV and cardiac outcomes found that reduced short-term HRV was associated with incident atrial fibrillation and cardiac death in the general population. The Copenhagen data added epidemiological weight to the relationship between autonomic function and arrhythmia risk in people without established heart disease, extending the signal from post-MI populations into community samples. 4 / Promising

The critical synthesis across these studies: in patients with known heart disease, the HRV-mortality relationship is strong, consistent, and mechanistically established at a level that warrants a rating of 5/Solid. In asymptomatic men in the community, the association is real and directionally consistent but smaller in magnitude and requires interpretation alongside other markers rather than in isolation. The wearable ecosystem presents consumer HRV data without acknowledging that the strongest evidence comes from a clinical instrument in a population with established disease, not from an optical wristband in a healthy man who has been optimizing his sleep.

What HRV Actually Measures

Heart rate variability is the millisecond variation between consecutive heartbeats, governed by the autonomic nervous system’s continuous calibration of cardiac output. Most consumer wearables measure RMSSD, root mean square of successive differences, during overnight sleep. RMSSD is specific to parasympathetic (vagal) nervous system activity: when you breathe in, your heart rate accelerates slightly; when you breathe out, it slows. This oscillation is what HRV captures. 5 / Solid

The clinical HRV measurement is a 24-hour Holter monitor calculating SDNN. The ATRAMI study established that SDNN below 70ms after MI predicted cardiac mortality with a relative risk of 3.2. Consumer wearables estimate RMSSD from optical pulse sensing during sleep: reasonably accurate for individual trends, not validated as a standalone clinical screening tool, and not comparable across different device brands. 4 / Promising

Normative values for healthy men aged 40 to 49: approximately 35 to 55 milliseconds. Values below 25 ms are associated with elevated cardiovascular risk. The clinically meaningful signal is not a single morning reading but a sustained directional decline over four to eight weeks without an identifiable acute explanation.

The Five Reasons HRV Declines

Reason 1: Autonomic aging. HRV declines approximately one to two milliseconds per year after age 30, driven by progressive reduction in parasympathetic tone. A man with HRV of 65 at 28 and 42 at 41 may be entirely normal. This is expected and does not require clinical intervention.

Reason 2: Training load. Intense training suppresses parasympathetic tone for 24 to 72 hours. The man who trains five days a week with high intensity and inadequate sleep will consistently show suppressed HRV. The wearable industry provides this explanation. It is sometimes correct.

Reason 3: Cortisol dysregulation. Chronic sympathetic overdrive, driven by sustained high cortisol, directly suppresses parasympathetic activity. The high-performing executive who has been running at full throttle for a decade accumulates allostatic load. Cortisol directly inhibits vagal outflow. The cortisol-HRV connection is mechanistic and well-documented.

Reason 4: Sleep apnea. OSA affects an estimated 25 to 34 percent of middle-aged men and is massively underdiagnosed. During apneic events, blood oxygen falls, the brain triggers micro-arousals, and sympathetic surges occur 20 to 60 times per hour. The Oura ring reports “excellent sleep.” The man stops breathing forty times per night. His HRV is low because his autonomic nervous system is fighting a hypoxic crisis the device cannot see.

Reason 5: Subclinical cardiovascular disease. This is the reason the optimization community does not discuss, because the wearable cannot see it and the protocol cannot fix it. Population studies find that men with the lowest HRV quartile have significantly higher rates of incident coronary artery disease and cardiac mortality over five to ten year follow-up. The mechanism: endothelial dysfunction impairs the nitric oxide-mediated vasodilation that allows the autonomic nervous system to modulate cardiac output smoothly. Inflammation suppresses vagal tone through cytokine effects on brainstem nuclei. A man whose coronary arteries are accumulating calcium, whose hs-CRP is 3.4 mg/L, whose endothelium is compromised, has a parasympathetic nervous system working against upstream resistance that no magnesium or cold plunge can overcome.

The device gives you the same number in all five scenarios. Only a cardiologist can tell you which one is operating.

The Voices That Are Right About the Wrong Thing

Andrew Huberman covers autonomic physiology with genuine scientific depth. His content on vagal tone, RMSSD, and the parasympathetic-sympathetic balance is mechanistically sound. What it does not address is the clinical meaning of a chronically declining HRV in a man who is following every protocol correctly. He is a PhD neuroscientist at Stanford. He has never ordered a CAC score. He cannot say: “I have watched men with HRV values in your range show up three years later with acute coronary syndrome, and here is what connected the two.” That is not a criticism of his intelligence. It is a description of what a cardiologist knows that a neuroscientist does not.

The Whoop company’s documentation frames low HRV almost entirely as a training and recovery optimization problem. Their primary resource for HRV gives population averages and training guidance without any reference to the established clinical literature connecting HRV to cardiovascular mortality. A man with a CAC score of 200 and declining HRV is told by Whoop that he is “not fully recovered.”

He is not told that his declining HRV, in the context of his risk profile, warrants a cardiologist’s attention.

The Honesty Scale

HRV as a predictor of cardiovascular mortality in patients with known heart disease: 5 / Solid Kleiger et al. 1987 and La Rovere et al. 1998 (ATRAMI), replicated across multiple cohorts. The post-MI HRV-mortality relationship is clinical fact and enters risk stratification guidelines.

HRV as a cardiac risk proxy in asymptomatic men: 4 / Promising Tsuji et al. Framingham data, CARDIA cohort, and Copenhagen City Heart Study all show association with incident cardiac events in general populations. Mechanism is biologically plausible and well-supported. Should be interpreted alongside other biomarkers, not in isolation.

Specific wearable HRV values as clinical thresholds: 3 / Early Wearable RMSSD correlates with ECG-derived RMSSD at approximately r=0.85 to 0.90 in research settings. Good enough for trend tracking; not validated for clinical decision-making. Device algorithms are proprietary and not interchangeable.

Improving HRV through a behavioral protocol prevents cardiac events: 2 / Theoretical No randomized controlled trial shows that improving wearable-measured HRV through behavioral protocols reduces cardiovascular events. The optimization industry inverted the evidence: HRV predicts events; improving HRV through protocols has not been proven to reduce them.

What to Do This Week

1. Look at your wearable’s 90-day HRV trend, not this morning’s reading. A consistent directional decline over three months without an acute explanation, meaning no illness, no major change in training load, no significant alcohol increase, no identified stressor, is the signal worth taking seriously. Single readings are noise. The trend is the signal.

2. If your HRV has been declining for three months or more and you have any of the following, schedule a cardiologist evaluation this month: age above 40 with a first-degree male relative who had a cardiac event before 65; ApoB not measured or known to be elevated; untreated sleep apnea symptoms including snoring, morning headaches, or unrefreshing sleep; or hs-CRP above 2 mg/L on prior testing.

3. Request a fasting insulin, ApoB, and hs-CRP alongside your next lipid panel. These three numbers tell you whether your declining HRV might be carrying a biological explanation beyond training load and stress. A normal LDL does not close the question. ApoB and hs-CRP open the next one.

4. If you have not had a home blood pressure assessment, get one this week. Not a single clinic reading. Multiple readings across different times of day over two to three days. Masked hypertension, blood pressure that is normal in a physician’s office and elevated outside it, affects an estimated 15 to 30 percent of middle-aged men and is a direct suppressant of HRV through chronic sympathetic loading.

5. If your physician tells you your LDL is fine and your HRV decline is a training problem without examining the CAC and ApoB picture, ask specifically: “Is there any reason to consider a coronary calcium score given my HRV trend and age?” That question, asked directly, opens a clinical conversation that the standard annual physical does not.

The Whoop is not broken. It just cannot tell you which of five explanations is operating in your specific cardiovascular anatomy. That distinction requires someone who has held the catheter.